Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Restasis Cyclosporine Ophthalmic Emulsion 005

Research Leaders

5 sponsors active, led by Allergan

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (1)
Phase 4 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05613660Not ApplicableCompleted

A Proof of Science, Dose-Response Study to Evaluate the Safety, Efficacy of Different Dosages of Test Treatments

NCT00648986Phase 4CompletedPrimary

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

NCT00986427Phase 2CompletedPrimary

Restasis for Treatment of Brittle Nails

Showing all 3 trials

Research Network

Common Treatments

  • Restasis Cyclosporine Ophthalmic Emulsion 0051
  • Refresh Dry Eye Therapy1
  • Veg Collagen Peptide1
  • Bovine Collagen Peptide1
  • Tazarotene1

Active Sponsors

  • Allergan2
  • Julian M. Mackay-Wiggan1
  • Collagen Lifesciences Private Limited1
  • NovoBliss Research Pvt Ltd1
  • Columbia University1

Top Investigators

Related Conditions

  • Stiffness Of Joint Nec Involving Ankle And Foot In Mdr2411
  • Healthy1
  • Osteoarthritis Knee1
  • Mild To Moderate Acne1
  • Other Specified Diseases Of Hair And Hair Follicles1

Activity Timeline